

**SUBCOMMITTEE ON HEALTH -- 115TH CONGRESS  
ROLL CALL VOTE # 3**

**BILL:** H.R. 2026, Pharmaceutical Information Exchange Act

**AMENDMENT:** An amendment offered by Mr. Schrader, No. 1a, Health care economic information or scientific information provided to a payor, formulary or technology review committee, or other similar entity with knowledge and expertise in the area of health care economic analysis carrying out its responsibilities for the selection of drugs or devices for coverage, reimbursement, or other population-based health care management, shall not be considered false or misleading or any other form of misbranding under this section, or a violation of section 505, 510(k), 513(f), or 515 of this Act or section 351 of the Public Health Service Act, if it is truthful, nonmisleading, and based on competent and reliable scientific evidence and relates to an investigational use of a drug or device approved, granted marketing authorization, cleared, or licensed pursuant to section 505, 510(k), 513(f), or 515 of this Act or pursuant to section 351 of the Public Health Service Act, and to provide that scientific information includes clinical and pre-clinical data and results relating to an investigational use.

**DISPOSITION:** NOT AGREED TO, by a roll call vote of 13 yeas and 17 nays.

REPRESENTATIVE	YEAS	NAYS	PRESENT	REPRESENTATIVE	YEAS	NAYS	PRESENT
Mr. Burgess		X		Mr. Green	X		
Mr. Guthrie		X		Mr. Engel	X		
Mr. Barton		X		Ms. Schakowsky	X		
Mr. Upton		X		Mr. Butterfield			
Mr. Shimkus		X		Ms. Matsui	X		
Mrs. Blackburn				Ms. Castor	X		
Mr. Latta		X		Mr. Sarbanes	X		
Mrs. McMorris Rodgers		X		Mr. Lujan	X		
Mr. Lance		X		Mr. Schrader	X		
Mr. Griffith		X		Mr. Kennedy	X		
Mr. Bilirakis		X		Mr. Cardenas	X		
Mr. Long				Ms. Eshoo	X		
Mr. Bucshon		X		Ms. DeGette	X		
Mrs. Brooks		X		Mr. Pallone	X		
Mr. Mullin		X					
Mr. Hudson		X					
Mr. Collins		X					
Mr. Carter		X					
Mr. Walden		X					